Chimerix, Inc. (NASDAQ:CMRX) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Michelle LaSpaluto - VP of Strategic Planning and IR Mike Sherman - President and CEO Mike Andriole - Chief Financial and Business Officer Allen Melemed - Chief Medical Officer Josh Allen - CTO, Imipridones Conference Call Participants Naureen Quibria - Maxim Group Joseph Thome - Cowen and Company Soumit Roy - JonesTrading Maury Raycroft - Jefferies Operator Good morning, ladies and gentlemen, and we ...

Chimerix, Inc. (NASDAQ:CMRX) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Michelle LaSpaluto – Vice President of Strategic Planning and Investor Relations Mike Sherman – President and Chief Executive Officer Allen Melemed – Chief Medical Officer Josh Allen – Chief Technology Officer-Imipridones Mike Andriole – Chief Scientific Officer Conference Call Participants Kevin Strang – Jefferies Naureen Quibria – Maxim Group Ed White – H.C. Wainwright Joe Thome – Cowen and Company So ...

May Corporate Update Forward-Looking Statements 2 These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop its drug candidates including ONC201, DSTAT and BCV; the sufficiency of the data from the current clinical trial of ...

March Corporate Update Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop its drug candidates including ONC201, DSTAT and BCV; the sufficiency of the data from the current clinical trial of ...

February Corporate Update Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop its drug candidates including ONC201, DSTAT and BCV; the sufficiency of the data from the current clinical trial ...

Chimerix, Inc. (NASDAQ:CMRX) Q4 2020 Earnings Conference Call February 25, 2021 8:30 AM ET Company Participants Michelle LaSpaluto - VP, Strategic Planning & IR Mike Sherman - President & CEO Allen Melemed - CMO Mike Andriole - CFO/CBO Randall Lanier - CSO Josh Allen - Interim CTO Conference Call Participants Ed White - H.C. Wainwright Soumit Roy - Jones Trading Joseph Thome - Cowen and Company Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Fourth Quarter and Year-End 2020 Earnings ...

November Corporate Update Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop DSTAT and BCV, including the initiation, progress and results of the Phase 3 clinical trial of DSTAT in AML and t ...

Chimerix, Inc. (NASDAQ:CMRX) Q3 2020 Earnings Conference Call November 5, 2020 8:30 AM ET Company Participants Michelle LaSpaluto - VP, Strategic Planning & IR Michael Sherman - CEO, President & Director Allen Melemed - Chief Medical Officer Michael Andriole - Chief Business Officer, Secretary & CFO Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Third Quarter 2020 Earnings Conference Call. I would now like to introduce you to your host for today's call, ...

Chimerix, Inc. (NASDAQ:CMRX) Q2 2020 Earnings Conference Call August 10, 2020 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President, Strategic Planning & Investor Relations Mike Sherman - President & Chief Executive Officer Randall Lanier - Chief Science Officer Mike Andriole - Chief Financial & Business Officer Allen Melemed - Chief Medical Officer Conference Call Participants Phil Nadeau - Cowen and Company Soumit Roy - JonesTrading Operator Good morning, ladies and gentlemen and welcome to ...

July Corporate Update Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop DSTAT and BCV, including the initiation of a Phase 2/3 clinical study for DSTAT in COVID-19 and a Phase 3 clinical tr ...